ROJAS RESTREPO, Jessica L., CABALLERO OTEYZA, Andrés, HÜBSCHER, Katrin, HABERSTROH, Hanna, FLIEGAUF, Manfred, KELLER, Bärbel, KOBBE, Robin, WARNATZ, Klaus, EHL, Stephan, PROIETTI, Michele und GRIMBACHER, Bodo, 2022. Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: Experience from a monocentric study. Freiburg: Universität.
Elsevier - Harvard (with titles)Rojas Restrepo, J.L., Caballero Oteyza, A., Hübscher, K., Haberstroh, H., Fliegauf, M., Keller, B., Kobbe, R., Warnatz, K., Ehl, S., Proietti, M., Grimbacher, B., 2022. Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: Experience from a monocentric study. Universität, Freiburg. https://doi.org/10.3389/fimmu.2021.786516
American Psychological Association 7th editionRojas Restrepo, J. L., Caballero Oteyza, A., Hübscher, K., Haberstroh, H., Fliegauf, M., Keller, B., Kobbe, R., Warnatz, K., Ehl, S., Proietti, M., & Grimbacher, B. (ca. 2022). Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: Experience from a monocentric study [Cd]. Universität. https://doi.org/10.3389/fimmu.2021.786516
Springer - Basic (author-date)Rojas Restrepo JL, Caballero Oteyza A, Hübscher K, Haberstroh H, Fliegauf M, Keller B, Kobbe R, Warnatz K, Ehl S, Proietti M, Grimbacher B (2022) Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: Experience from a monocentric study. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Rojas Restrepo, Jessica L./ Caballero Oteyza, Andrés/ Hübscher, Katrin/ Haberstroh, Hanna/ Fliegauf, Manfred/ Keller, Bärbel/ Kobbe, Robin/ Warnatz, Klaus/ Ehl, Stephan/ Proietti, Michele/ Grimbacher, Bodo, Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: Experience from a monocentric study, Freiburg 2022.